FILANA THERAPEUTICS, INC.
FLNA · XNASCIK 1069530fmd_1SCEB6XXMG1NZGY16FT8HZGH4JManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | – | – | – | – | – | – | – | – | – |
| Research and development | 9 | 8 | 3 | – | – | 25 | 68 | 89 | 70 | 27 |
| Total operating expenses | 15 | 12 | 7 | 5 | 6 | 33 | 80 | 106 | 141 | 95 |
| Operating income | (15) | (12) | (7) | (5) | (6) | (33) | (80) | (106) | (141) | (95) |
| Interest and investment income | 0 | 0 | 0 | 0 | 0 | 0 | 3 | – | – | – |
| Other non-operating income (expense) | – | – | – | – | – | 0 | 1 | 1 | 0 | (0) |
| Income before taxes | – | – | – | – | – | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | – | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | – | – | – |
| Net income | (15) | (12) | (7) | (5) | (6) | (32) | (76) | (97) | (24) | (91) |
| Net income to common shareholders | – | – | – | – | – | – | (76) | (97) | (68) | (91) |